Discussing the future of clinical trials in Sweden

Three industry profiles discussed the future of clinical trials in Sweden and its impact on life sciences in a podcast.

How do recent regulatory changes affect the possibilities for clinical trials and what are the consequences for the life science sector and patients in Sweden? SwedenBIO’s CEO Jessica Martinsson recently visited Sjukvårdspodden together with Peter Asplund, the government’s former investigator on clinical trials and Adam Szulkin, ecosystem partner at Roche to discuss the issue.

“Implementation is where the problem lies, getting hospitals and doctors to be able to recruit patients to the studies, that’s where the key to the solution lies”, began Jessica Martinsson.


Peter Asplund explained that Sweden is far behind other Nordic countries: “In the report we submitted to the government, we assessed the situation as worrying and stressed that there are signs that the situation is deteriorating over time. The study showed that as little as 20% or less of the requests that go to the health sector actually lead to concrete cooperation, he explained, noting that Sweden runs the risk of ending up in a situation where the number of trials per hundred thousand inhabitants falls below one trial. This is significantly lower than in the other Nordic countries, where the corresponding figure is around three.

Adam Szulkin from Roche spoke from his own experience of conducting clinical trials in Sweden: “There are very big differences between different hospitals and regions where there are some that work well and some that do not. This is often because there are no doctors who have time to take on the clinical trial or infrastructure such as clinical research nurses or other staff who can work on these studies”, he commented.

Listen to the full podcast on Spotify.